Viome | A Viome Life Sciences, Inc. Company.

We provide the industry’s only direct-to-consumer healthcare test that analyzes microbial and human gene expressions (mRNA), with technology exclusively licensed from Los Alamos National Lab, in order to provide individuals with health insights and the nutrition they need.

By joining Viome, you are joining a revolutionary movement. A movement that – for the first time in human history – will make becoming ill a matter of choice, and not simply bad luck.

Scientists have worked for over a decade to develop this technology that offers unprecedented visibility into your body. With this, we can create a unique profile of the biochemistry and ecosystem inside of you, and make personalized, actionable, and adaptive recommendations for your health.

Our at-home tests are not just one-time tests, but your true health companion, enabling you to monitor your health over time. Your results and recommendations adapt to your changing ecosystem so you are always aware and taking action towards maximizing your vitality and lifespan.

The Viome team is made up of scientists, engineers, researchers and entrepreneurs who are passionate about radically improving the wellness of our customers.

Bold Capital Partners

Khosla Ventures

Physician Partners

Hambrecht Healthcare Growth Venture Fund

Nomad Capital Partners

Marc Benioff

Matthew Harris

WestRiver Group

Ezaki Glico

Ocgrow Ventures

Viome

🎉 Wrapping up National Dental Hygiene Month and National Orthodontic Health Month with a Milestone! 🎉

As October concludes, it's not just the commitment to dental and orthodontic health that we celebrate but also the advancements in science that have the power to transform lives. Today, we're especially proud to highlight Viome's CancerDetect Test for Oral & Throat.

🔍 Here's why this is a game-changer:

✅ Breakthrough Technology: The FDA granted the breakthrough device designation to the technology behind CancerDetect. The technology behind CancerDetect is the same cutting-edge technology that powers Viome's Intelligence wellness tests. The breakthrough designation helps the FDA identify new technology to focus on in order to expedite access to novel devices that will save lives and treat debilitating diseases. The Breakthrough Program's purpose is clear: to ensure patients have swifter access to life-changing medical devices by hastening their journey from development to patient use.

✅ First of Its Kind Early Detection: CancerDetect is the first-ever test to identify biomarkers associated with oral and throat cancers with unmatched accuracy, including early stages, with a specificity of 95% and a sensitivity of 90%.

✅ Addressing a Critical Gap: Designed primarily for individuals at a higher risk of these cancers, CancerDetect addresses an urgent need for innovative solutions. Early detection is pivotal; when these cancers are diagnosed in the early stages, the 5-year survival rate can soar to 84%, a stark contrast to the sobering statistics of less than 50% when detected late.

In the spirit of National Dental Hygiene & Orthodontic Health Month, we not only emphasize the importance of regular oral care but also champion early detection and timely intervention. CancerDetect™ is redefining the future of oral and throat cancer diagnosis and treatment.

Learn more: https://www.viomepro.com/

To everyone involved in its development and to those who will benefit from it - here's to a brighter, healthier tomorrow! 🌟 #NationalDentalHygieneMonth #NationalOrthodonticHealthMonth #CancerDetect #OralMicrobiome #OralHealth #EarlyDetectionMatters

Viome is committed to our mission: envisioning a world where chronic illness becomes a matter of choice, not fate. We recognize the enormity of this challenge and its complexities, yet we are confident that by bringing the best minds together, we can significantly reduce the impact of chronic diseases. We're privileged to have the backing of eminent scientists and physicians who champion Viome's effort to push microbiome science and technology forward.

The new Oral Health Pro with CancerDetect from Viome can help #dental professionals detect markers for oral cancers and other oral and systemic conditions. https://lnkd.in/g7KCkY8N

The new offering relies on Viome's proprietary RNA sequencing technology and AI to identify early biomarkers associated with oral and throat cancers

Domain Not Resolving

DNSSEC

LetsEncrypt

nginx

reCAPTCHA

Cloudflare CDN

IPv6

U.S. Server Location

Cloudflare Network Error Logging

ASP.NET

Chief Operating Officer

John Blanchard

Vice President, Data Science & Machine Learning

Hal Tily

VP & General Manager, Consumer Division

Rodrigo Hutt

Operations

Anél Visser

Director of Strategic Planning

Jessica Youngblood

Design Director

Kevin Woo

Head of Content, Design & Media

Lashaun Dale, MA, MPH

Head of Recruiting

Lilit Sloyan

Head of People

Michael Chen

Director, Customer Experience

Morris Wong

Andrew McCallum

Teymour Boutros-Ghali

Emeran Mayer

Daniel Kraft

Harish Consul

Raymond Kurzweil

Naveen Jain

Founder & CEO

Momo Vuyisich

Chief Science Officer

Guruduth Banavar

Founding CTO, Head of Discovery, AI & Engineering, GM of Diagnostics

Morri Chowaiki

Chief Sales Officer

Kal Raman

COO and President

Anu Jain

Vice President Community Relations, Viome

Rodrigo Hütt

VP, General Manager and Consumer Division

Angel Janevski

Head of Data and Analytics Solutions

Bold Capital Partners Portfolio Companies

Western US Companies With More Than $1M in Revenue (Top 10K)

Washington Companies With Less Than $50M in Revenue (Top 10K)

United States Late Stage Companies With More Than $1M in Revenue

Viome is a provider of comprehensive health insights designed to help people track their microbiome health, mitochondrial health, cellular health, and biological age. 

The company's insights help users to make suitable lifestyle and nutrition choices for them, enabling users to assess their internal eco-system with simple personalized recommendations.

Viome was established on October 1, 2016 by Naveen Jain in 	Bellevue, Washington.

Series D - Viome

Series C - Viome

Debt Financing - Viome

Series B - Viome

Better Health Group

Series A - Viome

Advertising, Business and Retail Services

Bellevue

Washington

United States

North America

Gut Microbiota Market Set to Reach US$ 3,600.1 Million by 2032, Growing at a Robust CAGR of 22.50% from 2024 to 2032

Viome secures $25M, hires former Amazon, Groupon, Samsung executive

Viome Raises $25M To Launch Diagnostic Division and Bring On Former Amazon SVP and Samsung Chief Digital Officer, Kal Raman, as Chief Operating Officer

Wellness startup Viome targets oral health with toothpaste and gel formulated via microbiome data

Viome Launches the First Personalized AM/PM Toothpaste & Gel Formulated Using Oral Microbiome Data and AI to Support Whole-body Health

Viome Is Partnering with Henry Schein to Provide Better Access to Oral Health Pro™ With CancerDetect™

A comprehensive health test that analyzes the activities in your oral microbiome, gut microbiome, and cells using RNA sequencing to provide health scores and personalized food recommendations.

Custom supplement capsules formulated based on your test results, containing vitamins, minerals, herbs, extracts, and amino acids tailored to your needs.

A personalized blend of probiotics and prebiotics designed to support your gut health, based on your Gut Intelligence Test results.

Personalized oral lozenges containing prebiotics, probiotics, and postbiotics to support oral health, based on your Oral Health Intelligence Test results.

A test that analyzes gut microbial gene expression to provide health scores and personalized food recommendations for gut health.

A test that analyzes oral microbial gene expression to provide health scores and personalized food recommendations for oral health.

Canada

France

Europe

Philippines

Asia

Cyprus

HTML5

Comodo PositiveSSL Certificates

GoDaddy Premium DNS

Amazon EC2

Facebook

Disqus

jQuery

Amazon Route 53

Yotpo

SolarWinds Loggly

Viome owns Viome Life Sciences

Viome is a precision nutrition company that aims to prevent and reverse chronic diseases by digitizing and decoding each individual's biology, starting with the gut microbiome. They analyze RNA (gene expression) to gain a comprehensive understanding of an individual's body and provide personalized food recommendations and made-to-order supplements. Viome is focused on advancing precision diagnostics and therapeutics for chronic diseases, cancer, and aging.

news impact assignment basic	general
public peers	general
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general
company summary	general
signals	general
crunchbase trigger	general	Nov 25, 2024 9:06 AM	48b6fdd2
crunchbase profile	general	Nov 25, 2024 11:36 AM	57d52aa3
li profile	general
translate crunchbase fundingrounds	general	Nov 25, 2024 2:15 PM	8ef65a44
peers	general
news basic	general
bundesanzeiger	filings
financials download nd	financials
private financials	financials

COM:VIOME

Viome